<DOC>
	<DOC>NCT01710826</DOC>
	<brief_summary>To assess in healthy adult subjects: - The tolerability and safety of ascending repeated oral doses of Genz-682452. - The pharmacokinetic parameters of Genz-682452 after ascending repeated oral doses. - The pharmacodynamics of Genz-682452 after ascending repeated oral doses.</brief_summary>
	<brief_title>A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Genz-682452 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Body weight between 50.0 and 95.0 kg, inclusive, if male and between 40.0 and 85.0 kg inclusive, if female, body mass index between 18.0 and 30.0 kg/m^2, inclusive. Certified as healthy by a comprehensive clinical assessment. Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness. Frequent headaches and/or migraine, recurrent nausea and/or vomiting. Blood donation, any volume, within 2 months before inclusion. Symptomatic postural hypotension. History or presence of drug or alcohol abuse. Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen, antihepatitis C virus (antiHCV) antibodies, antihuman immunodeficiency virus 1 and 2 antibodies (antiHIV1 and anti HIV2 Ab). Positive result on urine drug screen.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>